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Of Pools, Oceans and the Dead Sea 
 
Samir K. Ballas  Thomas Jefferson University 
 
In a comprehensive study in this issue of Blood, Carden and colleagues described the importance of the 
tonicity of intravenous fluids used in the treatment of patients with sickle cell disease (SCD) during vaso-
occlusive crises. Hypertonic fluids decreased sickle red blood cell (sRBC) deformability, increased 
occlusion and increased sRBC adhesion in microfluidic human microvasculature models. Hypotonic 
fluids decreased sRBC adhesion but prolonged sRBC transit time. Fluids with intermediate tonicities 
resulted in optimal changes that reduced the risk of vaso-occlusion.1 
 
Osmosis is the movement of a neutral solvent across a semipermeable (red cell) 
membrane from a less concentrated solution into a more concentrated one. This movement 
equalizes the concentration of solutes on each side of the membrane. Tonicity, on the other hand, 
is the ability of a solution to make water move into or out of a cell by osmosis.  It depends on the 
concentration of all solutes in the solution i.e. its osmolarity.  A solution with low osmolarity is 
hypotonic and vice versa. Solutions having the same osmolarity are isotonic.2,3 
Water in pools and rivers is hypotonic compared to sea water but water from the dead sea 
is hypertonic. Swimming in the ocean or sea is relatively easier than swimming in a pool or river 
due to the buoyancy of seawater containing about 3.5% salt. Floating rather than swimming is 
the rule in the dead sea due to its hypertonicity with about 34.2% salt. Metaphorically, the red 
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blood cell (RBC) maintains its normal shape, shrinks or balloons depending on the tonicity of the 
extracellular solution in which it is suspended.  
 
It is generally believed that aggressive treatment of the vaso-occlusive crisis (VOC) at its 
onset would shorten its duration with fewer complications.4 The rational approach to abort a 
VOC is to treat it as early as possible where tissue ischemia and inflammation are in their early 
stages. The standard of care of anti-VOC therapy to abort a crisis includes a trial of hydration, 
anti-inflammatories, analgesics and adjuvants.4 Hydration often requires the administration of 
intravenous (IV) fluids. Fluids that are usually used for hydration are shown in Figure 1A. The 
choice of a certain fluid varies greatly among institutions and providers. The recent guidelines of 
the National Heart, lung, and Blood Institute to treat the complications of sickle cell disease 
(SCD) did not adequately address this issue.5,6 In addition, a recent Cochrane review of fluid 
replacement therapy for acute episodes of pain in people with SCD found no randomized 
controlled trials that have assessed the safety and efficacy of different routes, types or quantities 
of fluid.7  
 
In this issue of Blood Carden et al1 conducted elegant studies to determine the tonicity of 
the desirable IV fluid to hydrate patients with VOC. The scheme is illustrated in Figure 1B. 
Sickle RBC exposed to admixtures with the highest sodium level of 141 mEq/L (hypertonic 
solution) impacted sRBC biomechanics due to dehydration (xerocytosis) with increased mean 
corpuscular hemoglobin concentration (MCHC) and decreased mean corpuscular volume (MCV) 
associated with increased cytoplasmic viscosity and increased membrane rigidity leading to 
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decreased deformability and increased tendency for occlusion under normoxic and hypoxic 
conditions in the microfluidic human microvascular models used by the authors. This is similar 
to the xerocytosis described in hemoglobin SC disease.8 On the other hand, exposure of sRBC 
admixtures to hypotonic solution with sodium of 103 mEq/L caused water gain with decreased 
surface area/volume ratio transforming sRBC to swollen spherocytes with significantly 
decreased deformability and increased risk of occlusion in the normoxic microfluidic models 
used due to the fact that over swollen spherocytes prolonged the transit times of sRBC in 
capillary-sized microchannels.  Admixtures with sodium concentrations of 111 - 122 mEq/L 
appeared to optimize changes in sRBC deformability, in part due to ideal changes in the MCHC, 
the most sensitive predictor of hemoglobin S polymerization and microvascular occlusion and in 
part due to optimization of the surface area to volume ratio necessary for sRBCs to traverse 
capillary microchannels.  
 
In addition to the salutary effects of isotonic IV fluids to treat VOCs by preventing or 
minimizing vaso-occlusion, the authors proceeded to show the effects of the tonicity of IV fluids 
on adhesion of sRBC to vascular endothelium and laminin. Admixtures of sRBC with sodium 
concentration of 141 mEq/L demonstrated increased adhesion to both human endothelium and 
laminin. On the other hand, admixtures of sRBC with sodium concentration of 103 mEq/L 
showed decreased adhesion to endothelium and subendothelium matrix probably due to the fact 
that the hydrated swollen spherocytes may alter cell membrane contact points with the 
endothelium and subendothelium.9 This effect however, seems to be offset by the prolongation 
of the transit time of swollen spherocytes in capillary-sized microchannels.  
 
4 
 
This study presents a seminal translational approach to determine the appropriate IV 
fluids to be used in the management of patients with SCD during VOCs. The authors are aware 
that their study did not specify the type of sRBCs such as reticulocytes, dense cells, etc. with the 
hope to overcome these limitations in future projects. They are also aware that plasma 
components affect the rheology of sRBCs beyond their effect on tonicity.10  The authors did 
specify the intravenous route of fluid administration and the tonicity of the fluids used. They did 
not however, address the quantity to be used and followed during hospitalization. Patients with 
sickle cell anemia are known to have inability to concentrate urine. Urinary osmolality of up to 
400 to 450 mOsm/kg is often seen in adult patients with sickle cell anemia after water 
deprivation conditions. Perhaps, this should be considered in choosing the tonicity of the fluids 
to be used for hydration. 
This well-designed study indicates the need for clinical randomized trials to determine 
the safety and efficacy of different routes, types and quantities of fluids administered to patients 
with different types of SCD during VOCs. 
The author claims no conflict of interest. 
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Legend to Figure: 
Figure 1:  A. Intravenous fluids that are usually used to treat hydration in patients 
with sickle cell disease. B. Red blood cells suspended in hypertonic 
solution lose water shrink and are transformed to dehydrated xerocytes. 
Suspended in hypotonic solution, red blood cells gain water, swell and are 
transformed to spherocytes. Figure 1B adapted from Mariana Ruiz 
Villareal and the Khan Academy. 
https://www.khanacademy.org/science/biology/membranes-and-
transport/diffusion-and-osmosis/a/osmosis. Used by permission via the 
Attribution-Noncommercial -Share Alike 3.0 United States (CC BY-NC-
SA 3.0 US). 
